Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the effect of renal function on the PK of a 0.25
mg single oral dose of bevenopran in humans and to assess the safety and tolerability of
bevenopran in patients with varying degrees of renal impairment and in healthy subjects.